Allogene Therapeutics Inc ALLO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALLO is a good fit for your portfolio.
News
-
Allogene Therapeutics Announces Q2 Investor Conference Participation
-
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
-
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
-
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
-
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
-
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Trading Information
- Previous Close Price
- $3.36
- Day Range
- $3.26–3.37
- 52-Week Range
- $2.23–6.89
- Bid/Ask
- $3.26 / $3.27
- Market Cap
- $555.47 Mil
- Volume/Avg
- 15,805 / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,570.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 361
- Website
- https://www.allogene.com
Comparables
Valuation
|
Metric
|
ALLO
|
PRLD
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.11 | 0.86 | 4.92 |
Price/Sales | 5,570.25 | — | 265.86 |
Price/Cash Flow | — | — | — |
Price/Earnings
ALLO
PRLD
CLDX
Financial Strength
|
Metric
|
ALLO
|
PRLD
|
CLDX
|
|---|---|---|---|
Quick Ratio | 12.10 | 10.67 | 13.69 |
Current Ratio | 12.38 | 10.79 | 13.87 |
Interest Coverage | — | — | — |
Quick Ratio
ALLO
PRLD
CLDX
Profitability
|
Metric
|
ALLO
|
PRLD
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −32.62% | −38.93% | −30.49% |
Return on Equity (Normalized) | −40.48% | −43.41% | −33.19% |
Return on Invested Capital (Normalized) | −37.53% | −42.59% | −32.85% |
Return on Assets
ALLO
PRLD
CLDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rxfncctbq | Knmt | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bybpbgqst | Glkxlbj | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Srykmrkjl | Vynfg | $99.6 Bil | |
MRNA
| Moderna Inc | Hcccgft | Qgnt | $38.8 Bil | |
ARGX
| argenx SE ADR | Ynpjqtxy | Tnt | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Mgcmmjbv | Bych | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ljpshsrv | Vwtsws | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nszfrrwc | Nsjxldl | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ldzvjgsll | Fczmfbk | $12.4 Bil | |
INCY
| Incyte Corp | Lzjkyrsz | Spxzpm | $11.9 Bil |